Down 60%: 3 oversold ASX 200 shares to buy in June

The ASX 200 has been strong in parts, but not every share has enjoyed the ride.

In fact, some of the market’s highest-quality names have been sold down heavily over the past 12 months, potentially creating a buying opportunity for investors.

With that in mind, here are three oversold ASX 200 shares that could be in the buy zone in June:

Cochlear Ltd (ASX: COH)

The first ASX 200 share to look at is Cochlear.

The hearing solutions leader’s shares have fallen more than 60% over the past 12 months following a disappointing performance in FY 2026.

This is a big move for a company with a long history of innovation, global market leadership, and exposure to a large medical need. Cochlear’s products can make a meaningful difference to patients with severe hearing loss, and demand for hearing solutions should continue to grow as populations age.

For patient investors, this could be a chance to look again at a high-quality healthcare business after a major reset.

CSL Ltd (ASX: CSL)

Another ASX 200 share that looks oversold is CSL. The biotherapeutics giant has also fallen around 60% over the past 12 months, which is a remarkable decline for one of the ASX’s traditional blue-chip shares.

CSL has faced a difficult period as investors reassessed both its growth outlook and valuation. Weak earnings updates, restructuring plans, and softer medium-term guidance all weighed heavily on sentiment, particularly after management lowered expectations around growth in key areas such as flu vaccines and China albumin sales.

Despite these challenges, CSL’s core business remains exposed to important areas of healthcare, including immunology, haematology, vaccines, and iron deficiency. Healthcare demand is not driven by short-term consumer sentiment. That gives CSL a more defensive foundation than many cyclical businesses.

If management can restore confidence in the earnings outlook, this fallen giant could have plenty of recovery potential.

Xero Ltd (ASX: XRO)

A final ASX 200 share to consider is Xero. The cloud accounting software provider has fallen approximately 60% over the past 12 months, reflecting the broader pressure on software valuations.

Xero’s share price may be under pressure, but its platform remains deeply embedded in small business finance. Once customers connect invoicing, payroll, payments, bank feeds, reporting, and advisers to the platform, switching can be difficult.

The company also has room to keep expanding its role beyond accounting, helping small businesses manage more of their financial operations.

The road back may not be smooth. But after such a heavy fall, Xero could be a top ASX 200 recovery idea for June.

The post Down 60%: 3 oversold ASX 200 shares to buy in June appeared first on The Motley Fool Australia.

More reading

• Historic: Here’s why CSL shares are looking very interesting right now
• These 3 ASX healthcare stocks have been crushed in 2026. They could be set for a comeback
• Should I buy CSL shares in June?
• After CSL’s 60% share price crash, insiders are starting to buy
• How I’d invest $20,000 in ASX shares before the end of FY26

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.